Author: [AUTHOR] Published on 1/1/2020 12:00:00 AM

Huiming Xia, PhD, US Food and Drug Administration, Silver Spring, MD

Dr. Xia expects that his ASCPT membership will allow him to be more connected to professionals in the field of clinical pharmacology. He is also anticipating learning more drug development from the industry perspective. He enjoys the Annual Meeting as a place where he can meet friends and see the exciting updates and progression in the field. Dr. Xia likes being part of the Early Development & Drug Safety Community where he works together with other Steering Committee members to discuss and organize webinars. By participating in this capacity, he is able to learn from the discussion of the interesting topics in the field.

Dr. Xia believes that clinical pharmacology and translational medicine are very important to determine the right dose for the right patient population to achieve the best benefit‐risk balance. Dr. Xia is working as a clinical pharmacology reviewer at the US Food and Drug Administration. He reviews oncology drug submissions and provides recommendations from the regulatory perspective on the drug development process. Dr. Xia and his colleagues work together with the applicant to identify the optimal dose for oncology drugs.

ASCPT is a platform for scientists to share and disseminate clinical pharmacology and translational science knowledge, expertise, and updates in the field of clinical pharmacology. Dr. Xia believes that ASCPT has a positive impact on the field through providing leadership, education, advocacy, and resources, enabling clinical pharmacologists to achieve their career goals. He hopes that in the future, ASCPT will continue to act as a platform for clinical pharmacologists to grow and help advance the field.

Dr. Xia has been a member of ASCPT since 2018. He currently serves as the Vice Chair of the Early Development & Drug Safety Community and has presented an ASCPT webinar.